Pulmonx, Inc.: Series C $32M

Posted in I - Series C, Q - 1Q10, R - WEST, X - Device (COPD), X - Device (Pulmonary), XX - CA

Pulmonx (Redwood City, CA) a commercial-stage medical device company focused on minimally invasive devices for the diagnosis and treatment of COPD and other pulmonary disorders, closed a $32M Series C financing. Participants include HealthCap, Kleiner Perkins Caufield & Byers, De Novo Ventures, Latterell Venture Partners, MedVenture Associates, Montreux Equity Partners and Posco BioVentures.

Feb

2010

Epizyme, Inc.: Series B $8M

Posted in I - Series B, Q - 4Q09, R - NORTH EAST, X - Epigenetics, X - Oncology, X - Therapeutic Platform, XX - MA

Epizyme (Cambridge, MA) a development-stage biopharma company focused on histone methyltransferases inhibitors in oncology indications, closed a $8M Series B financings, bringing the total round to $40M. Participants include New Enterprise Associates, Bay City Capital, Amgen Ventures, Astellas Venture Partners, MPM Capital and Kleiner Perkins Caufield and Byers.
Note: 2009 Year-in-Review Trend Analysis Coming 15 [...]

Jan

2010

Spinal Modulation, Inc.: Series C $27.4M

Posted in I - Series C, Q - 4Q09, R - WEST, X - Device (Spine), XX - CA

Spinal Modulation (Menlo Park, CA) a development-stage medical device company focused on a spinal cord stimulator system for treating chronic intractable pain, closed a $27.4M Series C financing. Participants include Johnson & Johnson Development Corp., DFJ InCube Ventures, Raffles Venture Partners, DeNovo Ventures, DFJ ePlanet, Kleiner Perkins Caufield & Byers and MedVenture.
Note: 2009 Year-in-Review Trend [...]

Jan

2010

Tethys Bioscience, Inc.: Series D $25M

Posted in I - Series D, Q - 4Q09, R - WEST, X - Device (Diabetes), X - Device (Diagnostic), XX - CA

Tethys Bioscience (Emeryville, CA) a commercial-stage diagnostics company focused on type II diabetes risk assessment through the measurement of multiple biomarkers, closed a $25M Series D financing. Participants include Capital AG, Wasatch Advisors, Mohr Davidow Ventures, Kleiner Perkins Caulfield & Byers and Intel Capital.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Jan

2010

Epizyme, Inc.: Series B $32M

Posted in I - Series B, Q - 4Q09, R - NORTH EAST, X - Epigenetics, X - Oncology, X - Therapeutic Platform, XX - MA

Epizyme (Cambridge, MA) a development-stage biopharma company focused on histone methyltransferases inhibitors in oncology indications. Participants include Bay City Capital, Amgen Ventures, Astellas Venture Management, MPM Capital and Kleiner Perkins Caufield and Byers.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.

Jan

2010

Nodality, Inc.: Series C $3.5M

Posted in I - Series C, Q - 4Q09, R - WEST, X - Device (Diagnostic), XX - CA

Nodality (San Francisco, CA) a development-stage molecular diagnostics company focused on hematological malignancies and autoimmune disorders, closed a $3.5M Series C financing. Participants have included Kleiner Perkins Caufield & Byers, Maverick Capital, Pfizer and TPG Ventures.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.

to top of page...